It's not how he speaks; it's what he says. Market says he said nothing to impress. Otherwise wouldn't you think the stock would have rise. Savvy investors look deep into the company and they don't like what they see now. Gave it the benefit of the doubt earlier this year, but now they're looking close as they should. Are you?
And I have been there for all 200% and more. There is no shame in critiquing someone who is making mistakes and hurting the company. And complaining about the CEO mispronouncing the name of a competing drug is in no way making fun of his speech.
News 
Market Data 
Discover 
